Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Texas MPN Workshop 2022 | The management of polycythemia vera with cytoreductive drug therapy

Tiziano Barbui • 22 Aug 2022
Texas MPN Workshop 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Hydroxyurea Interferon Ropeginterferon alfa-2b Ruxolitinib

In this video, Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, discusses the role of cytoreductive therapy in the management of patients with polycythemia vera (PV) who are at high risk for thrombosis, and further highlights other treatment approaches for these patients. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Tiziano Barbui

COVID-19 and MPNs: updates from the ELN study
Tiziano Barbui • 10 Nov 2022
New guidelines for the treatment and management of polycythemia vera 10:20
New guidelines for the treatment and management of polycythemia vera
Tiziano Barbui • 6 Oct 2022
The impact of ruxolitinib on the long-term survival of patients with MF 3:24
The impact of ruxolitinib on the long-term survival of patients with MF
Tiziano Barbui • 22 Aug 2022
COVID-19 and MPN updates 6:00
COVID-19 and MPN updates
Tiziano Barbui • 22 Aug 2022

Related Videos

Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach 2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors 1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS 10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
The value of fedratinib for the treatment of patients with MF in the second-line setting 1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals